851684-46-3

Upstream product

• 16064-08-7 6-iodoquinazolin-4(3H)-one 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 1373622-18-4 4-chloro-6-iodoquinazoline hydrochloride 
• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 
• 98556-31-1 4-chloro-6-iodoquinazoline 

Downstream Products

• 851545-81-8 4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-formylquinazoline 
• 908306-43-4 4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-quinazoline-6-carboxylic acid methyl ester 
• 1432450-93-5 (4-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)phenyl)(piperidin-1-yl)methanone 
• 1432450-92-4 (3-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)phenyl)(piperidin-1-yl)methanone 
• 1432450-91-3 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(4-(piperidin-1-ylmethyl)phenyl)quinazolin-4-amine 
• 1432450-90-2 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(3-(piperidin-1-ylmethyl)phenyl)quinazolin-4-amine 
• 1432450-88-8 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(3-(piperidin-1-yl)phenyl)quinazolin-4-amine 
• 1432450-87-7 (4-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)phenyl)(morpholino)methanone 
• 1432450-86-6 (3-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-quinazolin-6-yl)phenyl)(morpholino)methanone 
• 1432450-85-5 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(4-(morpholinomethyl)phenyl)quinazolin-4-amine 
• 1432450-84-4 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(3-(morpholinomethyl)phenyl)quinazolin-4-amine 
• 1432450-83-3 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(4-morpholinophenyl)quinazolin-4-amine 
• 1432450-82-2 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(3-morpholinophenyl)quinazolin-4-amine 
• 1432451-01-8 NEU-624 

Relevant academic research and scientific papers

Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis

Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns b

4-Aminoquinazoline derivatives and methods of use thereof

This invention relates to novel 4-aminoquinazolines, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and HER-2.

QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY

A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt: (I) wherein Rx represents a group represented by the formula(II): where R1 represents a hydrogen atom, an alkyl group which may be substituted or the like, Z represents -O-, -N(R10)- or the like, R10 represents a hydrogen atom, an alkyl group or the like, R2 represents a hydrogen atom, an alkyl group which may be substituted or the like, R18 represents a hydrogen atom, an alkyl group which may be substituted or the like, R19 represents an alkyl group which may be substituted or the like, W1 represents a non-aromatic nitrogenated heterocyclic group which may be substituted, and R17 represents a hydrogen atom, an alkyl group which may be substituted or the like; R3 and R4 independently represent a hydrogen atom, an alkyl group which may be substituted or the like; X represents -O-, -S-, -N(R12)- or the like; R12 represents a hydrogen atom, an alkyl group or the like; and A represents a phenyl group which may be substituted or the like. The compound can inhibit both EGF receptor tyrosine kinase and HER2 tyrosine kinase.

Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors

Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Methods of treating hyperproliferative diseases in mammals are also disclosed.